AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.69 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.67 -0.02 (-0.54%) 7:46 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.69 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.67 -0.02 (-0.54%) 7:46 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Zacks News
AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
by Zacks Equity Research
AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune's Candidate Fails in Alzheimer's Disease Study
by Zacks Equity Research
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
Do Options Traders Know Something About AC Immune (ACIU) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.
Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected
by Zacks Equity Research
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy
by Zacks Equity Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales
by Zacks Equity Research
Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study
by Zacks Equity Research
AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Company News for Mar 24, 2020
by Zacks Equity Research
Companies in the news are: HAS, PCG, WTRH, ACIU
Moderna (MRNA) Catches Eye: Stock Jumps 6.4%
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.